A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression
This phase II trial in patients with stage II and stage III breast cancer will test the
feasibility of using cDNA microarray as a measure of a tumor's biological response to
chemotherapeutic agents by characterizing the cDNA expression patterns in breast cancer
before and after primary chemotherapy. Thirty-six patients receive docetaxel/capecitabine
induction chemotherapy followed by surgery and doxorubicin/cyclophosphamide adjuvant therapy
(TX/AC). We will determine the response rate of TX induction therapy and the toxicities of
the sequential combinations (TX/AC). We will also obtain tumor tissue for correlative
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Adverse Events
Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.
JoAnne Zujewski, M.D.
National Cancer Institute (NCI), National Institutes of Health (NIH)
United States: Federal Government
|National Naval Medical Center||Bethesda, Maryland 20889|